博士，副教授，硕士/博士生导师

电子邮箱: luojing117@hust.edu.cn

通讯地址:湖北省武汉市硚口区航空路13号华中科技大学同济医学院生殖健康研究所                    

学术经历:

2010-2015年，在华中科技大学同济医学院攻读博士学位，研究方向为中性粒细胞在肿瘤免疫中的作用机制；

2015-2018年，在华中科技大学同济医学院免疫系从事博士后研究，开展肿瘤代谢产物乳酸调控肿瘤相关巨噬细胞极化机制研究；

2018-2021年，在暨南大学生物医学转化研究院从事二期博士后研究，开展STING信号通路介导gd T细胞抗肿瘤功能机制研究。

学术成果：

1.主持国家自然科学基金青年项目1项

2.主持中国博士后基金特别资助项目1项

3.主持中国博士后基金面上项目2项

4.华中科技大学人才引进基金1项

研究方向：

1.免疫细胞调控妊娠相关疾病的分子机制研究；

2. STING信号通路在生殖免疫中的调控机理研究。

代表论文：

1. Na Liu#, Jing Luo#, Dong Kuang#, Sanpeng Su, Yaqi Duan, Yu Xia, Zhengping Wei, Xiuxiu Xie, Bingjiao Yin, Fang Chen, Shunqun Luo, Huicheng Liu, Jing Wang, Kan Jiang, Feili Gong, Zhaohui Tang, Xiang Chen, Huabin Li, Zhuoya Li, Arian Laurence, Guoping Wang*, Xiangping Yang*. Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2 alpha-mediated tumor progression. Journal of Clinical Investigation. 2019; 129: 631-646. (#co-first author, IF=14.808, JCR 1区).

2. Jing Luo, Jian-Feng Yao, Xiao-fei Deng, Xiao-dan Zheng, Min Jia, Yueqin Wang, Yan Huang, Jian-hua Zhu*. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res, 2018.2.9, 37(1): 23. (IF=11.161，JCR 1区).

3. Jing Luo, Binxia Ming, Cai Zhang, Xiafei Deng, Pingfei Li, Zhengping Wei, Yu Xia, Kan Jiang, Hong Ye, Wanli Ma, Zheng Liu, Huabin Li, Xiangping Yang*, Lingli Dong*. IL-2 Inhibition of Th17 Generation Rather Than Induction of Treg Cells Is Impaired in Primary Sjögren's Syndrome Patients. Frontiers in Immunology. 2018.8.13. DOI:10.3389/fimmu.2018.01755 (IF=7.561，JCR 1区).

4. Jing Luo, Shengli Wang, Zhenlong Zhou, Yin Zhao. Ad- and AAV8-mediated ABCA1 gene therapy in a murine model with retinal ischemia/reperfusion injuries. Molecular Therapy Methods & Clinical Development. 2021 Jan 26;20:551-558. (IF=6.698, JCR 2区)

5. Jing Luo, Huanhuan Guo, Zhoufu Liu, Tao Peng, Xianting Hu, Miaomiao Han, Xiangping Yang, Xuhong Zhou*, Huabin Li*.Analysis of Peripheral B Cell Subsets in Patients With Allergic Rhinitis. Allergy Asthma Immunol Res, 2018.5, 10(3): 236~243（IF=5.764，JCR 3区）

6. Mingyue Tao ^#, Jing Luo ^#, Tong Gu ^#, Xiaojuan Yu, Zhen Song, Yali Jun, Hao Gu, Kairong Han, Xiujuan Huang, Weiyong Yu, Su'an Sun, Zhengwei Zhang, Lu Liu, Xiaofei Chen, Li Zhang, Chao Luo, Qilong Wang. LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma. Cell Death Dis. 2021 Sep 13;12(9):845.(IF=8.469, JCR 1区)

7. Jianhua Zhu^#＊, Jing Luo^#, Yongchao Li, Min Jia, Yueqin Wang, Yan Huang, Shuhong Ke. HMGB1 induces human non-small cell lung cancer cell motility by activating integrin αvβ3/FAK through TLR4/NF-κB signaling pathway. Biochem Biophys Res Commun. 2016 Nov 25；480（4）：522-527.（# co-first author, IF＝3.575，JCR 2区）

8. Tuanjie Wu#, Bin Xu#, Guihua Zhao, Jing Luo*, Chao Luo*. IL-37 suppresses migration and invasion of gallbladder cancer cells through inhibition of HIF-1α induced epithelial-mesenchymal transition. Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8179-8185.（*co-corresponding author, IF=3.507，JCR 2区）

9. Quanli Yang#, Xia Liu#, Qihui Liu#, Zerong Guan, Jing Luo, Guangchao Cao, Ruitian Cai, Zhenhua Li, Yan Xu, Zengfeng Wu, Miaomiao Xu, Song Zhang, Fan Zhang, Hengwen Yang, Xuejia Lin, Meixiang Yang, Yangzhe Wu, Yunfei Gao, Richard A. Flavell, Jianlei Hao*, Zhinan Yin*. Roles of mTORC1 and mTORC2 in controlling gamma delta T1 and gamma delta T17 differentiation and function. Cell Death and differentiation. DOI:10.1038/s41418-020-0500-9.(IF=15.828, JCR 1区)

10. Pingfei Li, Xiaofei Deng, Jing Luo, Yufei Chen, Guoyu Bi, Feili Gong, Zhengping Wei, Na Liu, Huabin Li, Laurence Arian, Xiangping Yang*. ATP6V0d2 mediates leucine-induced mTORC1 activation and polarization of macrophages. Protein & Cell. 2019; 10(8):615-619. 10.1007/s13238-019-0636-x.(IF=14.870, JCR 1区)

11. Chao Luo#, Yu Shu#, Jing Luo, Dan Liu, DS Huang, Y Han, C Chen, YC Li, Jiuming Zou, Jian Qin, Y Wang, Dong Li, Shanshan Wang, Guimei Zhang, Juan Chen*, Zuohua Feng*. Intracellular IL-37b interacts with Smad3 to suppress multiple signaling pathways and the metastatic phenotype of tumor cells. Oncogene. 2017; 36(20):2889-2899. (IF=9.867，JCR 1区).